CAR-T & Cellular Therapy Focus

Explore the latest updates and expert interviews

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Legend Biotech. This supporters no influence over the production of the content.

Latest videos Videos by disease NK-cell therapy Features Videos by topic Podcasts Expert editorial board

Welcome to CAR-T & Cellular Therapy Focus

Explore the latest updates in this field by hematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.

CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

Videos by Disease

Multiple Myeloma
Lymphoma
ALL
AML
CLL
MDS
1:26
Feasibility and safety of outpatient practice for recently approved CAR-T therapies
Radhika Bansal • 11 Dec 2022
1:09
Using BM and PET/CT to assess MRD status in myeloma & lymphoma patients post-CAR-T therapy
Radhika Bansal • 11 Dec 2022
1:00
Strategies to treat patients with multiple myeloma who relapse after autoSCT
Eileen Boyle • 12 Dec 2022
1:59
Investigating the mechanisms of initial & acquired resistance to BCMA CAR-T therapy in myeloma
Mehmet Samur • 10 Dec 2022
View All Videos
1:41
Advances in cellular therapies for lymphoma: the value of CAR-T therapy & optimizing patient outcome
Jason Westin • 11 Dec 2022
1:35
Update on Phase I study of plamotamab in R/R NHL
Krish Patel • 12 Dec 2022
5:42
Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCL
Nilanjan Ghosh • 8 Dec 2022
2:51
Novel agents vs. standard chemotherapy for first-line salvage treatment following CAR-T in LBCL
Gloria Iacoboni • 12 Dec 2022
View All Videos
1:52
Opportunities and challenges for dual-targeting CAR-T therapy in ALL
Regina Myers • 11 Dec 2022
2:32
Phase I study of CD22-targeted CAR-T therapy in patients with CD19-negative B-ALL
Regina Myers • 11 Dec 2022
2:20
Risk factors for success or failure of CD19-directed CAR-T therapy in children with B-ALL
Regina Myers • 11 Dec 2022
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
View All Videos
3:09
Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML
Evelyn Ullrich • 5 Dec 2022
2:05
Phase I results of rapidly manufactured Prgn-3006 Ultracar-T in R/R acute myeloid leukemia
David Sallman • 11 Dec 2022
1:55
Phase I/Ib safety study of PRGN-3006 UltraCAR-T in patients with R/R CD33-positive AML & HR-MDS
Nelli Bejanyan • 12 Dec 2022
4:38
Current status & progress in CAR-T therapy for hematological malignancies
Michael Bishop • 29 Nov 2022
View All Videos
2:57
Latest advances in CAR-T therapy for CLL and Richter’s transformation
Adam Kittai • 10 Dec 2022
2:10
Promising therapies for Richter’s transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-T
Adam Kittai • 10 Dec 2022
1:31
The advent of CAR-T therapy for CLL and emerging promising combinations
Constantine Tam • 12 Dec 2022
3:55
First-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda • 11 Dec 2022
View All Videos
1:55
Phase I/Ib safety study of PRGN-3006 UltraCAR-T in patients with R/R CD33-positive AML & HR-MDS
Nelli Bejanyan • 12 Dec 2022
1:31
The potential of bringing CAR-T therapy to MDS and challenges to overcome
Eric Padron • 9 Dec 2022
2:01
Strategies to manipulate the immune system in myeloid malignancies
Eunice Wang • 29 Sep 2022
3:47
The role of immunotherapy in the AML treatment landscape
Thomas Cluzeau • 12 Jun 2022
View All Videos

Videos by Topic

Nursing
Clinical Practice
Policy
Treatment
Toxicity
Manufacturing
1:51
The important role of nurses in the management of patients with multiple myeloma
Tiffany Richards • 26 Aug 2022
0:52
Nursing and CAR-T therapy
John Murray • 22 Mar 2022
2:29
The nurse’s role in CAR-T therapy
Michelle Kenyon • 14 Feb 2022
2:53
Supporting patients during CAR-T therapy
Michelle Kenyon • 14 Feb 2022
View All Videos
4:17
Using serum proteomics & the HT10 score to distinguish between infections & CRS after CAR-T therapy
Veit Buecklein • 9 Dec 2022
2:10
Promising therapies for Richter’s transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-T
Adam Kittai • 10 Dec 2022
3:06
Real-world data on prophylactic corticosteroid use with axi-cel in patients with R/R LBCL
Yi Lin • 10 Dec 2022
7:05
Developments in the use of bispecific antibodies in myeloma and challenges in this space
Mohamad Mohty • 10 Dec 2022
View All Videos
3:52
Cost-effectiveness of brexu-cel in adult patients with R/R ALL in the US
Michael Bishop • 29 Nov 2022
1:51
Expanding accessibility to CAR-T therapy
Nico Gagelmann • 28 Oct 2022
1:21
Approval of axi-cel in second-line for R/R LBCL & label update
Evandro Bezerra • 23 Apr 2022
2:38
Tackling inequalities in the field of stem cell transplantation and cellular therapies
Nico Gagelmann • 21 Mar 2022
View All Videos
2:57
Latest advances in CAR-T therapy for CLL and Richter’s transformation
Adam Kittai • 10 Dec 2022
1:41
Advances in cellular therapies for lymphoma: the value of CAR-T therapy & optimizing patient outcome
Jason Westin • 11 Dec 2022
1:52
Opportunities and challenges for dual-targeting CAR-T therapy in ALL
Regina Myers • 11 Dec 2022
1:35
Update on Phase I study of plamotamab in R/R NHL
Krish Patel • 12 Dec 2022
View All Videos
6:38
Comparison of the safety & efficacy of CAR-T therapy vs bispecifics in R/R multiple myeloma
Borja Puertas-Martinez • 8 Oct 2022
6:52
Long-term follow-up of allogeneic stem cell transplantation with omidubicel
Chenyu Lin • 5 Oct 2022
1:28
Leveraging technology to detect and mitigate CAR-T therapy-related toxicity remotely
Surbhi Sidana • 27 Aug 2022
2:08
Safety, efficacy and tolerability of ide-cel in the real-world
Surbhi Sidana • 27 Aug 2022
View All Videos
3:51
Donor-derived allogeneic CAR-T for B-ALL post-transplant
Claire Roddie • 7 Dec 2019
1:31
The importance of the European Medicines Agency in CAR-T development
Ulrich Jäger
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al. • 22 Sep 2018
3:08
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi • 12 Sep 2018
View All Videos

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Legend Biotech.

This supporters no influence over the production of the content.

If you are interested in becoming a supporter of The CAR-T & Cellular Therapy Focus, please contact us.

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals